Skip to main content
Attend an Event

UCP Professional Learning Series: Part 2: “New discoveries in the evolving world of genetics: diagnosis and treatment of cerebral palsy”​ - Dr. Michael Kruer

Thursday, September 29, 2022 | 5-6:30pm CST

Learning Objectives:

At the end of the session, attendees should be able to:

  • Discuss implications of evolving knowledge about causes of cerebral palsy on diagnosis
  • Discuss implications of evolving knowledge about causes of cerebral palsy on treatment

Gillette Children’s Accreditation Statement:

Continuing Medical Education (CME) Information:

Credit Designation1.5 AMA PRA Category 1 Credits™ | 1.5 Contact/Clock Hours

Physicians/APPs: Gillette Children’s is accredited by the Minnesota Medical Association (MMA) to provide continuing medical education (CME) for physicians and takes responsibility for the content, quality, and integrity of this educational activity. Gillette Children’s Specialty Healthcare designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™.  Physicians/APPs should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This activity is designed to meet the Minnesota Board of Nursing (MNBON) continuing education requirements for 1.5 contact hours. It is the participant’s responsibility to ascertain if this activity meets the mandatory continuing education requirements of the licensing board under which they practice.

Others: This activity is worth a maximum of 1.5 clock hours. It is the responsibility of the individual to determine if this activity meets their professional requirements for continuing education credit.

Disclosure Statement: Dr. Michael Kruer has disclosed relevant financial relationships with the following ineligible companies: Neurocrine Biosciences, Merz Therapeutics, Bridge Bio, PTC Therapeutics, Aeglea, and Medtronic. Dr. Kruer’s relevant financial relationships have been fully mitigated and no other planners of this educational activity have any relevant financial relationships with ineligible companies to disclose.

Questions: If you have any questions regarding this CME activity, please contact us at